Will AstraZeneca plc, Shire plc and Smith & Nephew plc help you survive Brexit?

Should you buy these three stocks ahead of the EU referendum? AstraZeneca plc (LON: AZN), Shire plc (LON: SHP) and Smith & Nephew plc (LON: SN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With the EU referendum less than a month away, many investors may be feeling somewhat nervous regarding the prospects for the FTSE 100 and the UK economy. This is entirely understandable since there’s a real possibility that Brexit might happen, which could cause the investment community to become increasingly risk-off in the short run.

In such a scenario, owning defensive stocks could be a sound move. That’s because they’re likely to be less positively correlated to the performance of the UK economy, which means that their profitability is less dependent on the macroeconomic outlook than is the case for many of their index peers. As such, defensive stocks could become increasingly popular over the short-to-medium term and buying them now could be a means of outperforming a volatile index.

Positive growth outlook

One stock that appears to fit the bill in terms of its defensive characteristics is pharmaceutical business AstraZeneca (LSE: AZN). Certainly, its bottom line has disappointed in recent years due to the loss of patents on blockbuster drugs. But with AstraZeneca embarking on a takeover spree, its long-term profit growth outlook is relatively positive.

Furthermore, AstraZeneca’s future financial performance is more dependent on the performance of its drugs in clinical trials than the performance of the UK economy. And with it having a beta of 0.9, AstraZeneca should provide a less volatile shareholder experience, which could prove to be a useful attribute if the FTSE 100 becomes highly volatile following Brexit.

Reasonable price

Also offering an outlook less positively correlated with the UK economy than most of its index peers is Smith & Nephew (LSE: SN). It has the added advantage over most stocks (including AstraZeneca) in that its business model is very consistent and reliable. In fact, Smith & Nephew has been able to increase its earnings in each of the last five years and with earnings growth of 2% pencilled-in for this year as well as 12% for next year, investor sentiment towards the company could improve.

That’s especially the case since Smith & Nephew trades on a price-to-earnings growth (PEG) ratio of only 1.4, which indicates that its shares offer strong growth prospects at a very reasonable price.

The Baxalta issue

Meanwhile, Shire (LSE: SGP) has a rather less certain future than many of its pharmaceutical peers. That’s because it recently agreed to a $32bn acquisition of Baxalta and while this positions the company for long-term profits growth, there are concerns that synergies won’t be met and that the two companies will fail to integrate as successfully as hoped.

Clearly, such concerns are often present during major mergers and acquisitions. However, Shire’s PEG ratio of 0.9 indicates that they seem to be priced-in, with it having a relatively wide margin of safety. And with the company having a strong pipeline of new treatments, it could prove to be a star performer even if Brexit causes uncertainty in the short run for the FTSE 350.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »